These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 25556500)

  • 21. Association between common risk factors and molecular subtypes in breast cancer patients.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer.
    Khokher S; Qureshi MU; Mahmood S; Nagi AH
    Asian Pac J Cancer Prev; 2013; 14(5):3223-8. PubMed ID: 23803108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of preoperative
    Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
    Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group.
    Anderson BM; Kamrava M; Wang PC; Chen P; Demanes DJ; Hayes JK; Kuske RR
    Brachytherapy; 2016; 15(6):788-795. PubMed ID: 27743957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?
    Jones T; Neboori H; Wu H; Yang Q; Haffty BG; Evans S; Higgins S; Moran MS
    Ann Surg Oncol; 2013 Sep; 20(9):2866-72. PubMed ID: 23661183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
    Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status.
    Bertaut A; Mounier M; Desmoulins I; Guiu S; Beltjens F; Darut-Jouve A; Ponnelle T; Arnould L; Arveux P
    Eur J Cancer Care (Engl); 2015 Nov; 24(6):920-8. PubMed ID: 25757548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
    Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
    Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors.
    de Gregorio A; Friedl TWP; Hering E; Widschwendter P; de Gregorio N; Bekes I; Janni W; Dayan D; Huober JB
    Oncology; 2021; 99(12):780-789. PubMed ID: 34535596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA; Genovesi D; Trignani M; DI Nicola M
    Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.